Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health and hospice companies, today announced that on June 7, 2011, it closed the acquisition of Beacon Hospice, Inc. Two Rhode Island agencies remain subject to final Rhode Island state regulatory approval. As previously discussed in an April 18, 2011 press release, Beacon is a provider of hospice services with 23 free-standing locations and one inpatient unit, serving the states of Massachusetts (11), Maine (5), New Hampshire (5), Rhode Island (2) and Connecticut (1). The purchase price paid for Beacon was $125 million.
Beacon Hospice is headquartered in Boston, Mass., and is regarded as one of the premier hospice companies in the New England region. Total annualized revenue for Beacon in 2010 was approximately $80 million. This transaction is expected to add $0.05 to $0.07 to Amedisys' earnings in 2011 excluding one-time transaction related costs.